Concentrix Reports $1.52B Goodwill Impairment Leading to Significant Net Loss in Fiscal 2025 Annual Report

summarizeSummary

Concentrix Corp filed its annual 10-K, reporting a $1.52 billion non-cash goodwill impairment charge for fiscal year 2025, resulting in a net loss of $1.28 billion, despite a 2.2% increase in revenue.

check_boxKey Events

• Significant Goodwill Impairment

  The company recorded a non-cash goodwill impairment charge of $1,523.3 million for the fiscal year ended November 30, 2025. This was determined after an interim quantitative assessment on November 1, 2025, following a sustained decrease in the market price of its common stock.

• Substantial Net Loss

  Concentrix reported a net loss of $(1,278.9) million for fiscal year 2025, a significant decline from a net income of $251.2 million in fiscal year 2024, primarily due to the goodwill impairment.

• Modest Revenue Growth

  Revenue increased by 2.2% to $9,825.8 million in fiscal year 2025, up from $9,618.9 million in the prior fiscal year.

• Increased Share Repurchase Authorization

  The board of directors extended the share repurchase program in January 2025, increasing the remaining authorization to $600 million. As of November 30, 2025, approximately $439.5 million remained available for repurchases.

auto_awesomeAnalysis

Concentrix Corp's annual 10-K filing reveals a substantial non-cash goodwill impairment charge of $1.52 billion for fiscal year 2025, which was the primary driver of a net loss of $1.28 billion. This impairment, triggered by a sustained decrease in the company's stock price, indicates a significant re-evaluation of the carrying value of assets from past acquisitions. While the company achieved a modest 2.2% revenue growth, the impairment overshadows operational performance. Investors should note the material impact on the company's financial position and the underlying challenges reflected by the asset write-down. The company also increased its share repurchase authorization and made debt repayments, but these are secondary to the impairment's magnitude.